NCT00570778 - Efficacy and Safety of QVA149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) | Biotech Hunter

Enrollment

154

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2008

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG

indacaterol/glycopyrrolate

Inhalation capsule indacaterol/glycopyrrolate 300/50 μg inhaled once daily via a single dose dry powder inhaler for 7 days.

DRUG

indacaterol

Inhalation capsule indacaterol supplied as 300 μg capsules inhaled once daily via a single dose dry powder inhaler for 7 days.

DRUG

placebo

Placebo inhalation capsules inhaled once daily via a single dose dry powder inhaler for 7 days.

Trial Locations (22)

Novartis Investigator Site, St Louis

Novartis Investigator Site, Charlotte

Novartis Investigator site, Raleigh

Novartis Investigator Site, Antwerp

Novartis Investigator Site, Ghent

Novartis Investigator Site, Jambes

Novartis Investigator Site, Sankt Vith

Novartis Investigator Site, Moncton

Novartis Investigator Site, Montreal

Novartis Investigator site, Toronto

Novartis Investigator Site, Bad Wörishofen

Novartis Investigator Site, Berlin

Novartis Investigator Site, Frankfurt

Novartis Investigator Site, Mainz

Novartis Investigator Site, Rudersdorf

Novartis Investigator Site, Wiesbaden

Novartis Investigator Site, Almelo

Novartis Investigator Site, Breda

Novartis Investigator site, Eindhoven

Novartis investigator site, Heerlen

Novartis Investigator Site, Nijmegen

Novartis Investigator Site, Veldhoven